LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Open

BrancheGesundheitswesen

21.45 -0.23

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

21.45

Max

21.45

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.6M -21M
Verkäufe	14M 54M
Gewinnspanne	-39.611
Angestellte	178
EBITDA	-3.8M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-3.62% downside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1B 2.2B
Vorheriger Eröffnungskurs	21.68
Vorheriger Schlusskurs	21.45

Nachrichtenstimmung

By Acuity

50%

159 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Mai 2026, 23:31 UTC

Heiße Aktien

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20. Mai 2026, 22:52 UTC

Wichtige Markttreiber

Osisko Shares Fall on Planned Convertible Notes Offering

20. Mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20. Mai 2026, 23:44 UTC

Ergebnisse

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20. Mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20. Mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20. Mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20. Mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20. Mai 2026, 23:14 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20. Mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20. Mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20. Mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20. Mai 2026, 22:10 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20. Mai 2026, 22:00 UTC

Ergebnisse

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20. Mai 2026, 21:38 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20. Mai 2026, 21:27 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20. Mai 2026, 21:20 UTC

Ergebnisse

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20. Mai 2026, 21:19 UTC

Ergebnisse

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20. Mai 2026, 21:18 UTC

Ergebnisse

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20. Mai 2026, 21:16 UTC

Ergebnisse

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

-3.62% Nachteil

12-Monats-Prognose

Durchschnitt 20.75 USD -3.62%

Hoch 21.5 USD

Tief 17 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

159 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.